Imunon, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023; unaudited. Imunon is a clinical-stage biotechnology company developing non-viral nucleic-acid therapies and vaccines. Its lead program, IMNN-001, is in Phase II development for advanced ovarian cancer.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $0 | $125,000 | $0 | $250,000 |
| Research and development | $3.13 million | $3.23 million | $5.75 million | $6.32 million |
| General and administrative | $2.34 million | $2.88 million | $5.40 million | $5.75 million |
| Total operating expenses | $5.47 million | $6.10 million | $11.16 million | $12.07 million |
| Operating loss | $5.47 million | $5.98 million | $11.16 million | $11.82 million |
| Net loss | $5.56 million | $6.04 million | $11.15 million | $16.52 million |
| Basic and diluted loss per share | $0.61 | $0.87 | $1.28 | $2.59 |
The company reported no Q2 or first-half 2023 revenue; the prior-year licensing revenue was recognition of a Hisun contract that was fully amortized by year-end 2022. With no material revenue base, operating margins are not meaningful.
- At June 30, cash and cash equivalents were $6.61 million, available-for-sale short-term investments were $17.40 million, and accrued investment interest receivable was $0.08 million. The company cited approximately $24.1 million in these resources.
- Current assets were $26.73 million and current liabilities $6.12 million, yielding working capital of approximately $20.61 million. Total assets were $28.72 million; stockholders’ equity was $21.52 million.
- Operating cash use was $10.78 million in the first half. Investing activities provided $3.64 million; financing activities used $3.75 million, including repayment of the SVB loan.
- The $6.0 million SVB loan was repaid in full on April 21, 2023, with $420,000 in early termination and end-of-term charges, for total payment of $6.42 million. No notes payable remained at quarter-end. Operating lease liabilities totaled $1.36 million.
- The company raised approximately $2.67 million net through its at-the-market equity facility during the first half, issuing 1,815,584 shares. Common shares outstanding were 9,251,981 at June 30, compared with 7,436,197 at December 31, 2022.
Changes versus the prior comparable period
- First-half net loss narrowed by about $5.37 million, largely because the 2022 period included $4.55 million of interest and offering costs associated with preferred stock that was issued and redeemed in Q1 2022. In 2023, investment income increased, while the company recorded a $329,158 loss on extinguishing the SVB debt.
- First-half operating expenses declined 7.6%. R&D spending on PLACCINE and manufacturing/CMC increased, while clinical and OVATION-related costs declined; G&A also decreased, primarily due to lower stock-based compensation.
- Cash, investments, and interest receivable fell from approximately $32.88 million at December 31, 2022 to approximately $24.09 million at June 30, 2023. The company also released $6.0 million of restricted cash after repaying the SVB loan.
- At December 31, 2022, the company wrote off a $13.4 million IPR&D asset and the earn-out milestone liability after concluding the relevant requirements were not achieved. These were prior-year items, not Q2 2023 charges.
Outlook, risks, and unusual items
- Management expects continuing operating losses and substantial funding needs. It believes current resources, together with approximately $1.8 million of planned future New Jersey NOL sales, are sufficient to fund operations for 12 months from issuance of the financial statements. This is not a guarantee; additional financing may be required sooner or in greater amounts.
- OVATION 2 completed enrollment of 110 patients in September 2022; topline results were expected in the first half of 2024. A separate Phase 1/2 study of IMNN-001 with bevacizumab is planned to enroll 50 patients; initial second-look laparoscopy data are expected within one year after enrollment completes, with final PFS data about three years after completion.
- In July 2023, the FDA confirmed that a platform approach to preclinical toxicology testing could be used for updated SARS-CoV-2 genes without additional toxicology studies, according to the company. Imunon said it intended to select another PLACCINE pathogen target during 2023. These are development plans, not approved products or revenue guidance.
- Key risks include clinical and regulatory uncertainty, trial enrollment and execution, the need to raise capital, possible shareholder dilution, competition, intellectual-property risks, and the possibility that development timelines or costs change. If financing is unavailable, the company may need to delay, reduce, or terminate programs.
- Legal matters include an ongoing derivative shareholder suit for which the company said loss likelihood and range could not be determined. A securities class action was dismissed with leave to amend; the plaintiff did not amend within the deadline. A separate books-and-records case was dismissed without prejudice. The company paid approximately $583,500 under an arbitration award relating to one ThermoDox batch; the claim regarding another batch was denied.
- Management reported disclosure controls and procedures were effective at the reasonable-assurance level as of June 30, 2023, with no material changes to internal control over financial reporting identified during the quarter.
Important facts for investors to verify
- Whether the stated 12-month cash runway remains achievable given the pace of operating cash use and the timing and proceeds of planned NOL sales.
- OVATION 2 topline timing and results, and progress, enrollment, and data milestones for the bevacizumab combination study.
- Available capacity under the ATM facility, any subsequent share issuance, and the potential dilution from equity awards, options, and warrants.
- Whether PLACCINE development plans progress beyond preclinical work and whether additional financing or partners are secured.
- Developments in the derivative litigation and any subsequent updates to legal contingencies or cash requirements.